EarliTec Diagnostics Raises $21.5 Million To Accelerate Launch of EarliPoint Evaluation For Autism   

EarliTec Diagnostics raised $21.5 million in new financing, which it will use to boost commercialization of its EarliPoint Evaluation. EarliPoint is authorized by the FDA as an objective measurement tool to assist experts or trained clinicians in the diagnosis and assessment of autism in children aged 16 months to 30 months.;

As part of the EarliPoint Evaluation tool, children watch videos of social interactions on a tablet. An embedded biomarker tracks how the child focuses on the scenes and assesses the level of function on the core characteristics of autism – social disability, verbal ability, and non-verbal learning . . .